Announcements 2022
Update re. timing of Admission – 20/12/2022
Put Option re AZD1656 & £115,586 Subscription – 19/12/2022
Clinical Pilot Study for Early Lung Cancer Detection in China – 23/11/2022
Conduit Pharmaceuticals Proposed Listing – 09/11/2022
Total Voting Rights – 31/10/2022
Admission and Total Voting Rights – 04/10/2022
Total Voting Rights – 30/09/2022
Issue of Consideration Shares and Director Option Exercise – 29/09/2022
Holdings in Company – 28/09/2022
Interim results for the six months ended 30 June 2022 – 28/09/2022
Admission and Total Voting Rights – 26/09/2022
Subscription, Facility & Publication of Prospectus – 21/09/2022
Arcadia Clinical Trial Results Published for Cizzle Biotechnology’s Royalty Bearing interest in AZD1656 – 18/08/2022
Update on the Development of Proprietary Antibodies for Early-Stage Lung Cancer Detection Tests and Initial Indications in Detecting Other Cancers – 05/07/2022
Result of AGM – 27/06/2022
Marketing Agreement to Enhance Expansion in the USA – 16/06/2022
Posting of Annual Report and Notice of AGM – 01/06/2022
Results for the year ended 31 December 2021 – 30/05/2022
Strategic Alliance to develop and market early lung cancer detection in USA – 06/05/2022
Further Research Agreement with the University of York for Cancer Diagnosis and Therapy – 11/04/2022
Further positive outcomes from the Arcadia Clinical Trial by SGSC and Excalibur Medicines for Cizzle Biotechnology’s Royalty Bearing interest in AZD1656 – 07/03/2022
Holdings in Company – 18/02/2022
Total Voting Rights – 16/02/2022
Acquisition of Royalty Deal in Inflammatory Pulmonary and Cardiovascular Diseases – 14/02/2022
Holdings in Company – 04/02/2022
Royalty Strategic Alliance for Early Lung Cancer Detection in China – 03/02/2022
Holdings in Company – 02/02/2022
Holdings in Company – 02/02/2022
Holdings in Company – 02/02/2022
Holdings in Company – 19/01/2022
